Cooley advised AN2 Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering.AN2 Therapeutics, Inc. announced its upsized initial public offering of 4,600,000…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
